Vidarbha News

Prurigo Nodularis Pipeline Drugs and Companies Insight Report, 2021: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Prurigo Nodularis Pipeline Drugs and Companies Insight Report, 2021: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

October 14
03:05 2021
Prurigo Nodularis Pipeline Drugs and Companies Insight Report, 2021: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
DelveInsight Business Research LLP
DelveInsight’s, “Prurigo Nodularis – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Prurigo Nodularis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s “Prurigo Nodularis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Prurigo Nodularis pipeline landscapes. 

The report comprises Prurigo Nodularis pipelinedrug profiles, including clinical and non-clinical stage products. It also includes the Prurigo Nodularis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Prurigo Nodularis pipeline products.     

Prurigo Nodularis Overview

Prurigo nodularis is an intensely pruritic, chronic skin condition characterized by localized or generalized hyperkeratotic papules and nodules typically in a symmetrical distribution. Prurigo nodularis is accompanied by long-standing pruritus and is thought to develop as a reaction to repeated scratching in patients with Chronic Prurigo from various etiologies, including dermatological, systemic, infectious, and psychiatric. 

Some of the key takeaways from the Prurigo Nodularis Pipeline Report:

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Menlo Therapeutics, Trevi Therapeutics, Galderma, Dupixent, Amagen, Kiniksa Pharmaceuticals, Maruho, etc., are developing therapies for the treatment of Prurigo Nodularis.

  • Emerging therapies such as Serlopitant, Nalbuphine ER, Nemolizumab, Sanofi/ Regeneron, Apremilast, KPL-716, M118103, are expected to have a significant impact on the Prurigo Nodularis market in the coming years.

Get an overview of pipeline landscape @ Prurigo Nodularis Clinical Trials Analysis 

Prurigo Nodularis Pipeline Therapies along with Key Players:

  • Serlopitant :Menlo Therapeutics

  • Nalbuphine ER: Trevi Therapeutics

  • Nemolizumab: Galderma 

  • Sanofi/ Regeneron:Dupixent 

  • Apremilast: Amagen

  • KPL-716:Kiniksa Pharmaceuticals

  • M118103:Maruho

Scope of Prurigo Nodularis Pipeline Drug Insight    

  • Coverage: Global 

  • Major Players: Menlo Therapeutics, Trevi Therapeutics, Galderma, Dupixent, Amagen, Kiniksa Pharmaceuticals, Maruho, and others.

  • Pipeline Therapies: Serlopitant, Nalbuphine ER, Nemolizumab, Sanofi/ Regeneron, Apremilast, KPL-716, M118103, and others.

Table of Contents

1

Prurigo Nodularis Report Introduction

2

Prurigo Nodularis Executive Summary

3

Prurigo Nodularis Overview

4

Prurigo Nodularis-Analytical Perspective In-depth Commercial Assessment

5

Prurigo Nodularis Pipeline Therapeutics

6

Prurigo Nodularis Late Stage Products (Phase II/III)

7

Prurigo Nodularis Mid Stage Products (Phase II)

8

Prurigo Nodularis Early Stage Products (Phase I)

9

Prurigo Nodularis Preclinical Stage Products

10

Prurigo Nodularis Therapeutics Assessment

11

Prurigo Nodularis Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Prurigo Nodularis Key Companies

14

Prurigo Nodularis Key Products

15

Prurigo Nodularis Unmet Needs

16 

Prurigo Nodularis Market Drivers and Barriers

17

Prurigo Nodularis Future Perspectives and Conclusion

18

Prurigo Nodularis Analyst Views

19

Appendix

20

About DelveInsight

Get a customized pipeline report @ Prurigo Nodularis Drugs Pipeline Report

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/